Impact of NSAID and Triptan Use on Developing Chronic Migraine: Results From the American Migraine Prevalence and Prevention (AMPP) Study
Objectives To assess the influence of triptan or nonsteroidal anti‐inflammatory drug (NSAID) use on the likelihood of developing chronic migraine (CM) among persons with episodic migraine (EM). Background CM is common in tertiary headache care, and relative to EM, CM is associated with a number of d...
Saved in:
| Published in | Headache Vol. 53; no. 10; pp. 1548 - 1563 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Blackwell Publishing Ltd
01.11.2013
Wiley Subscription Services, Inc |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Objectives
To assess the influence of triptan or nonsteroidal anti‐inflammatory drug (NSAID) use on the likelihood of developing chronic migraine (CM) among persons with episodic migraine (EM).
Background
CM is common in tertiary headache care, and relative to EM, CM is associated with a number of deleterious outcomes, including higher headache‐related disability, reduced health‐related quality of life, and increased direct and indirect costs. Symptomatic medication use has emerged as an important risk factor for the development of CM. Limited evidence based on a single year of follow up suggests that the association between NSAID and triptan use with the onset of CM varies in a dose‐dependent manner that interacts with headache frequency. However, this interaction has never been explicitly studied. Herein, we evaluate results from a large‐scale, 5‐year, population‐based observational study to characterize these relationships and test the hypothesis that NSAID use may modify the effect of triptan use on CM onset.
Methods
In the American Migraine Prevalence and Prevention (AMPP) study, 11,249 participants had EM in 2005 and provided up to 5 years of annual follow‐up data. We analyzed the characteristics of persons with EM 1 year that predicted new onset CM in the subsequent year, focusing on treatment with NSAIDs and triptans as exposures. These adjacent years of data provide the basis for analysis and are termed “couplets.” Repeated measures logistic regression with a subject‐specific random intercept was used to model the likelihood of transition from EM to CM as a function of NSAID or triptan dose while controlling for a number of covariates including headache features, use of other medications, and the number of couplets per individual.
Results
The analysis included 9031 individuals with EM contributing up to 5 years of data and up to 4 couplets each. Results indicated that on average, 55% of the participants used NSAIDs in any given year and 2% transitioned to CM over subsequent years. Among the 20% using triptans, 3% per year transitioned to CM. Among persons with less than 10 headache days per month, frequency of NSAID use was associated with dose‐dependent reductions in risk of CM onset. Among those with 10‐14 headache days per month, increasing days per month of NSAID use was associated with increasing risk of CM onset. Increasing days per month of triptan use was associated with increased risk of transitioning to CM. Combination use of NSAIDs and triptans was not protective against transition to CM, but was also not statistically significantly associated with increased risk of CM onset.
Conclusion
Triptan use in EM is associated with an increased risk of CM onset that increases with days of medication use. For NSAIDs, effects depend on headache days per month. NSAIDs are protective in individuals with less than 10 headache days per month but associated with increased risk with 10 or more headache days per month. Combining a triptan and NSAID was not associated with a statistically significant increased risk of CM onset, whereas increased risk of CM onset was significantly associated with triptan monotherapy. |
|---|---|
| AbstractList | To assess the influence of triptan or nonsteroidal anti-inflammatory drug (NSAID) use on the likelihood of developing chronic migraine (CM) among persons with episodic migraine (EM).OBJECTIVESTo assess the influence of triptan or nonsteroidal anti-inflammatory drug (NSAID) use on the likelihood of developing chronic migraine (CM) among persons with episodic migraine (EM).CM is common in tertiary headache care, and relative to EM, CM is associated with a number of deleterious outcomes, including higher headache-related disability, reduced health-related quality of life, and increased direct and indirect costs. Symptomatic medication use has emerged as an important risk factor for the development of CM. Limited evidence based on a single year of follow up suggests that the association between NSAID and triptan use with the onset of CM varies in a dose-dependent manner that interacts with headache frequency. However, this interaction has never been explicitly studied. Herein, we evaluate results from a large-scale, 5-year, population-based observational study to characterize these relationships and test the hypothesis that NSAID use may modify the effect of triptan use on CM onset.BACKGROUNDCM is common in tertiary headache care, and relative to EM, CM is associated with a number of deleterious outcomes, including higher headache-related disability, reduced health-related quality of life, and increased direct and indirect costs. Symptomatic medication use has emerged as an important risk factor for the development of CM. Limited evidence based on a single year of follow up suggests that the association between NSAID and triptan use with the onset of CM varies in a dose-dependent manner that interacts with headache frequency. However, this interaction has never been explicitly studied. Herein, we evaluate results from a large-scale, 5-year, population-based observational study to characterize these relationships and test the hypothesis that NSAID use may modify the effect of triptan use on CM onset.In the American Migraine Prevalence and Prevention (AMPP) study, 11,249 participants had EM in 2005 and provided up to 5 years of annual follow-up data. We analyzed the characteristics of persons with EM 1 year that predicted new onset CM in the subsequent year, focusing on treatment with NSAIDs and triptans as exposures. These adjacent years of data provide the basis for analysis and are termed "couplets." Repeated measures logistic regression with a subject-specific random intercept was used to model the likelihood of transition from EM to CM as a function of NSAID or triptan dose while controlling for a number of covariates including headache features, use of other medications, and the number of couplets per individual.METHODSIn the American Migraine Prevalence and Prevention (AMPP) study, 11,249 participants had EM in 2005 and provided up to 5 years of annual follow-up data. We analyzed the characteristics of persons with EM 1 year that predicted new onset CM in the subsequent year, focusing on treatment with NSAIDs and triptans as exposures. These adjacent years of data provide the basis for analysis and are termed "couplets." Repeated measures logistic regression with a subject-specific random intercept was used to model the likelihood of transition from EM to CM as a function of NSAID or triptan dose while controlling for a number of covariates including headache features, use of other medications, and the number of couplets per individual.The analysis included 9031 individuals with EM contributing up to 5 years of data and up to 4 couplets each. Results indicated that on average, 55% of the participants used NSAIDs in any given year and 2% transitioned to CM over subsequent years. Among the 20% using triptans, 3% per year transitioned to CM. Among persons with less than 10 headache days per month, frequency of NSAID use was associated with dose-dependent reductions in risk of CM onset. Among those with 10-14 headache days per month, increasing days per month of NSAID use was associated with increasing risk of CM onset. Increasing days per month of triptan use was associated with increased risk of transitioning to CM. Combination use of NSAIDs and triptans was not protective against transition to CM, but was also not statistically significantly associated with increased risk of CM onset.RESULTSThe analysis included 9031 individuals with EM contributing up to 5 years of data and up to 4 couplets each. Results indicated that on average, 55% of the participants used NSAIDs in any given year and 2% transitioned to CM over subsequent years. Among the 20% using triptans, 3% per year transitioned to CM. Among persons with less than 10 headache days per month, frequency of NSAID use was associated with dose-dependent reductions in risk of CM onset. Among those with 10-14 headache days per month, increasing days per month of NSAID use was associated with increasing risk of CM onset. Increasing days per month of triptan use was associated with increased risk of transitioning to CM. Combination use of NSAIDs and triptans was not protective against transition to CM, but was also not statistically significantly associated with increased risk of CM onset.Triptan use in EM is associated with an increased risk of CM onset that increases with days of medication use. For NSAIDs, effects depend on headache days per month. NSAIDs are protective in individuals with less than 10 headache days per month but associated with increased risk with 10 or more headache days per month. Combining a triptan and NSAID was not associated with a statistically significant increased risk of CM onset, whereas increased risk of CM onset was significantly associated with triptan monotherapy.CONCLUSIONTriptan use in EM is associated with an increased risk of CM onset that increases with days of medication use. For NSAIDs, effects depend on headache days per month. NSAIDs are protective in individuals with less than 10 headache days per month but associated with increased risk with 10 or more headache days per month. Combining a triptan and NSAID was not associated with a statistically significant increased risk of CM onset, whereas increased risk of CM onset was significantly associated with triptan monotherapy. Objectives To assess the influence of triptan or nonsteroidal anti‐inflammatory drug (NSAID) use on the likelihood of developing chronic migraine (CM) among persons with episodic migraine (EM). Background CM is common in tertiary headache care, and relative to EM, CM is associated with a number of deleterious outcomes, including higher headache‐related disability, reduced health‐related quality of life, and increased direct and indirect costs. Symptomatic medication use has emerged as an important risk factor for the development of CM. Limited evidence based on a single year of follow up suggests that the association between NSAID and triptan use with the onset of CM varies in a dose‐dependent manner that interacts with headache frequency. However, this interaction has never been explicitly studied. Herein, we evaluate results from a large‐scale, 5‐year, population‐based observational study to characterize these relationships and test the hypothesis that NSAID use may modify the effect of triptan use on CM onset. Methods In the American Migraine Prevalence and Prevention (AMPP) study, 11,249 participants had EM in 2005 and provided up to 5 years of annual follow‐up data. We analyzed the characteristics of persons with EM 1 year that predicted new onset CM in the subsequent year, focusing on treatment with NSAIDs and triptans as exposures. These adjacent years of data provide the basis for analysis and are termed “couplets.” Repeated measures logistic regression with a subject‐specific random intercept was used to model the likelihood of transition from EM to CM as a function of NSAID or triptan dose while controlling for a number of covariates including headache features, use of other medications, and the number of couplets per individual. Results The analysis included 9031 individuals with EM contributing up to 5 years of data and up to 4 couplets each. Results indicated that on average, 55% of the participants used NSAIDs in any given year and 2% transitioned to CM over subsequent years. Among the 20% using triptans, 3% per year transitioned to CM. Among persons with less than 10 headache days per month, frequency of NSAID use was associated with dose‐dependent reductions in risk of CM onset. Among those with 10‐14 headache days per month, increasing days per month of NSAID use was associated with increasing risk of CM onset. Increasing days per month of triptan use was associated with increased risk of transitioning to CM. Combination use of NSAIDs and triptans was not protective against transition to CM, but was also not statistically significantly associated with increased risk of CM onset. Conclusion Triptan use in EM is associated with an increased risk of CM onset that increases with days of medication use. For NSAIDs, effects depend on headache days per month. NSAIDs are protective in individuals with less than 10 headache days per month but associated with increased risk with 10 or more headache days per month. Combining a triptan and NSAID was not associated with a statistically significant increased risk of CM onset, whereas increased risk of CM onset was significantly associated with triptan monotherapy. Objectives To assess the influence of triptan or nonsteroidal anti-inflammatory drug (NSAID) use on the likelihood of developing chronic migraine (CM) among persons with episodic migraine (EM). Background CM is common in tertiary headache care, and relative to EM, CM is associated with a number of deleterious outcomes, including higher headache-related disability, reduced health-related quality of life, and increased direct and indirect costs. Symptomatic medication use has emerged as an important risk factor for the development of CM. Limited evidence based on a single year of follow up suggests that the association between NSAID and triptan use with the onset of CM varies in a dose-dependent manner that interacts with headache frequency. However, this interaction has never been explicitly studied. Herein, we evaluate results from a large-scale, 5-year, population-based observational study to characterize these relationships and test the hypothesis that NSAID use may modify the effect of triptan use on CM onset. Methods In the American Migraine Prevalence and Prevention (AMPP) study, 11,249 participants had EM in 2005 and provided up to 5 years of annual follow-up data. We analyzed the characteristics of persons with EM 1 year that predicted new onset CM in the subsequent year, focusing on treatment with NSAIDs and triptans as exposures. These adjacent years of data provide the basis for analysis and are termed "couplets." Repeated measures logistic regression with a subject-specific random intercept was used to model the likelihood of transition from EM to CM as a function of NSAID or triptan dose while controlling for a number of covariates including headache features, use of other medications, and the number of couplets per individual. Results The analysis included 9031 individuals with EM contributing up to 5 years of data and up to 4 couplets each. Results indicated that on average, 55% of the participants used NSAIDs in any given year and 2% transitioned to CM over subsequent years. Among the 20% using triptans, 3% per year transitioned to CM. Among persons with less than 10 headache days per month, frequency of NSAID use was associated with dose-dependent reductions in risk of CM onset. Among those with 10-14 headache days per month, increasing days per month of NSAID use was associated with increasing risk of CM onset. Increasing days per month of triptan use was associated with increased risk of transitioning to CM. Combination use of NSAIDs and triptans was not protective against transition to CM, but was also not statistically significantly associated with increased risk of CM onset. Conclusion Triptan use in EM is associated with an increased risk of CM onset that increases with days of medication use. For NSAIDs, effects depend on headache days per month. NSAIDs are protective in individuals with less than 10 headache days per month but associated with increased risk with 10 or more headache days per month. Combining a triptan and NSAID was not associated with a statistically significant increased risk of CM onset, whereas increased risk of CM onset was significantly associated with triptan monotherapy. [PUBLICATION ABSTRACT] To assess the influence of triptan or nonsteroidal anti-inflammatory drug (NSAID) use on the likelihood of developing chronic migraine (CM) among persons with episodic migraine (EM). CM is common in tertiary headache care, and relative to EM, CM is associated with a number of deleterious outcomes, including higher headache-related disability, reduced health-related quality of life, and increased direct and indirect costs. Symptomatic medication use has emerged as an important risk factor for the development of CM. Limited evidence based on a single year of follow up suggests that the association between NSAID and triptan use with the onset of CM varies in a dose-dependent manner that interacts with headache frequency. However, this interaction has never been explicitly studied. Herein, we evaluate results from a large-scale, 5-year, population-based observational study to characterize these relationships and test the hypothesis that NSAID use may modify the effect of triptan use on CM onset. In the American Migraine Prevalence and Prevention (AMPP) study, 11,249 participants had EM in 2005 and provided up to 5 years of annual follow-up data. We analyzed the characteristics of persons with EM 1 year that predicted new onset CM in the subsequent year, focusing on treatment with NSAIDs and triptans as exposures. These adjacent years of data provide the basis for analysis and are termed "couplets." Repeated measures logistic regression with a subject-specific random intercept was used to model the likelihood of transition from EM to CM as a function of NSAID or triptan dose while controlling for a number of covariates including headache features, use of other medications, and the number of couplets per individual. The analysis included 9031 individuals with EM contributing up to 5 years of data and up to 4 couplets each. Results indicated that on average, 55% of the participants used NSAIDs in any given year and 2% transitioned to CM over subsequent years. Among the 20% using triptans, 3% per year transitioned to CM. Among persons with less than 10 headache days per month, frequency of NSAID use was associated with dose-dependent reductions in risk of CM onset. Among those with 10-14 headache days per month, increasing days per month of NSAID use was associated with increasing risk of CM onset. Increasing days per month of triptan use was associated with increased risk of transitioning to CM. Combination use of NSAIDs and triptans was not protective against transition to CM, but was also not statistically significantly associated with increased risk of CM onset. Triptan use in EM is associated with an increased risk of CM onset that increases with days of medication use. For NSAIDs, effects depend on headache days per month. NSAIDs are protective in individuals with less than 10 headache days per month but associated with increased risk with 10 or more headache days per month. Combining a triptan and NSAID was not associated with a statistically significant increased risk of CM onset, whereas increased risk of CM onset was significantly associated with triptan monotherapy. To assess the influence of triptan or nonsteroidal anti-inflammatory drug (NSAID) use on the likelihood of developing chronic migraine (CM) among persons with episodic migraine (EM). CM is common in tertiary headache care, and relative to EM, CM is associated with a number of deleterious outcomes, including higher headache-related disability, reduced health-related quality of life, and increased direct and indirect costs. Symptomatic medication use has emerged as an important risk factor for the development of CM. Limited evidence based on a single year of follow up suggests that the association between NSAID and triptan use with the onset of CM varies in a dose-dependent manner that interacts with headache frequency. However, this interaction has never been explicitly studied. Herein, we evaluate results from a large-scale, 5-year, population-based observational study to characterize these relationships and test the hypothesis that NSAID use may modify the effect of triptan use on CM onset. In the American Migraine Prevalence and Prevention (AMPP) study, 11,249 participants had EM in 2005 and provided up to 5 years of annual follow-up data. We analyzed the characteristics of persons with EM 1 year that predicted new onset CM in the subsequent year, focusing on treatment with NSAIDs and triptans as exposures. These adjacent years of data provide the basis for analysis and are termed "couplets." Repeated measures logistic regression with a subject-specific random intercept was used to model the likelihood of transition from EM to CM as a function of NSAID or triptan dose while controlling for a number of covariates including headache features, use of other medications, and the number of couplets per individual. The analysis included 9031 individuals with EM contributing up to 5 years of data and up to 4 couplets each. Results indicated that on average, 55% of the participants used NSAIDs in any given year and 2% transitioned to CM over subsequent years. Among the 20% using triptans, 3% per year transitioned to CM. Among persons with less than 10 headache days per month, frequency of NSAID use was associated with dose-dependent reductions in risk of CM onset. Among those with 10-14 headache days per month, increasing days per month of NSAID use was associated with increasing risk of CM onset. Increasing days per month of triptan use was associated with increased risk of transitioning to CM. Combination use of NSAIDs and triptans was not protective against transition to CM, but was also not statistically significantly associated with increased risk of CM onset. Triptan use in EM is associated with an increased risk of CM onset that increases with days of medication use. For NSAIDs, effects depend on headache days per month. NSAIDs are protective in individuals with less than 10 headache days per month but associated with increased risk with 10 or more headache days per month. Combining a triptan and NSAID was not associated with a statistically significant increased risk of CM onset, whereas increased risk of CM onset was significantly associated with triptan monotherapy. |
| Author | Serrano, Daniel Reed, Michael L. Buse, Dawn C. Runken, M. Chris Lipton, Richard B. Nicholson, Robert A. |
| Author_xml | – sequence: 1 givenname: Richard B. surname: Lipton fullname: Lipton, Richard B. organization: Albert Einstein College of Medicine/Montefiore Medical Center, NY, Bronx, USA – sequence: 2 givenname: Daniel surname: Serrano fullname: Serrano, Daniel organization: Vedanta Research, NC, Chapel Hill, USA – sequence: 3 givenname: Robert A. surname: Nicholson fullname: Nicholson, Robert A. organization: Mercy Health Research/Mercy Clinic Headache Center, MO, St. Louis, USA – sequence: 4 givenname: Dawn C. surname: Buse fullname: Buse, Dawn C. organization: Albert Einstein College of Medicine/Montefiore Medical Center, NY, Bronx, USA – sequence: 5 givenname: M. Chris surname: Runken fullname: Runken, M. Chris organization: GlaxoSmithKline, NC, Research Triangle Park, USA – sequence: 6 givenname: Michael L. surname: Reed fullname: Reed, Michael L. organization: Vedanta Research, NC, Chapel Hill, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23992516$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkU9v0zAYxi00xLrBhQ-ALHEZhwz_iZ2YW9Sua6WtVPsjEBfLSd6sHonTOcmgH4FvjdtuO3DCF_uVf8-j99FzhA5c6wCh95Sc0nA-r8CUp5QxQl-hERVMRrGk5ACNCKFJlCZxeoiOuu6eEBJLJd-gQ8aVYoLKEfozb9am6HFb4cV1Np9g40p84-26Nw7fdoBbhyfwCHW7tu4Oj1e-dbbAl_bOG-vgC76Cbqj7Dk992-B-BThrwNsiqJ8ZvPTwaGpwBezctyO43gbnk-xyufyEr_uh3LxFrytTd_Du6T5Gt9Ozm_Esuvh6Ph9nF5HlgtEIcpakEhijoogNU6URvMoVN8YkFSlzLqoQLS-LisdpwnJhSCULqbhQuSpywY_Ryd537duHAbpeN7YroK6Ng3boNI0Vk4JLlvwHKmmaslTEAf34D3rfDt6FIJoKTsK2MqGB-vBEDXkDpV572xi_0c99BIDugV-2hs3LPyV627TeNq13TevZWTbZvYIm2mts18PvF43xP7VMeCL0t8W5Hi-Sq-kPNdPf-V-BgaqJ |
| ContentType | Journal Article |
| Copyright | 2013 American Headache Society 2013 American Headache Society. Copyright © 2013 American Headache Society |
| Copyright_xml | – notice: 2013 American Headache Society – notice: 2013 American Headache Society. – notice: Copyright © 2013 American Headache Society |
| DBID | BSCLL CGR CUY CVF ECM EIF NPM 7TK 7U7 C1K K9. 7X8 |
| DOI | 10.1111/head.12201 |
| DatabaseName | Istex Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Neurosciences Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Toxicology Abstracts Neurosciences Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic ProQuest Health & Medical Complete (Alumni) Toxicology Abstracts MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1526-4610 |
| EndPage | 1563 |
| ExternalDocumentID | 3318721541 23992516 HEAD12201 ark_67375_WNG_CN7RFZ9H_X |
| Genre | article Research Support, Non-U.S. Gov't Journal Article Observational Study Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: McNeil‐Janssen Scientific Affairs LLC, Raritan, NJ (MJSA) – fundername: GlaxoSmithKline, Research Triangle Park, NC – fundername: National Institutes of Health, National Institutes of Neurological Disorders and Stroke funderid: K23048288 – fundername: NINDS NIH HHS grantid: K23NS048288 – fundername: NIA NIH HHS grantid: R01AG025119 – fundername: NIA NIH HHS grantid: R01AG022374-06A2 – fundername: NIA NIH HHS grantid: R01AG12101 – fundername: PHS HHS grantid: K23048288 – fundername: NIA NIH HHS grantid: R01AG034119 – fundername: NINDS NIH HHS grantid: K23 NS048288 – fundername: NINDS NIH HHS grantid: K23NS47256 – fundername: NINDS NIH HHS grantid: K23NS05140901A1 – fundername: NIA NIH HHS grantid: K23AG030857 |
| GroupedDBID | --- .3N .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 29I 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5HH 5LA 5RE 5VS 66C 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AAQQT AASGY AAWTL AAXRX AAZKR ABCQN ABCUV ABEML ABIVO ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHMBA AI. AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG COF D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS ECV EJD EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FYBCS G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO L7B LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ TEORI UB1 VH1 W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQ9 WQJ WRC WVDHM WXI WXSBR XG1 YCJ YFH YUY ZGI ZXP ZZTAW ~IA ~WT AAHQN AAIPD AAMMB AAMNL AANHP AAYCA ACRPL ACYXJ ADNMO AEFGJ AEYWJ AFWVQ AGHNM AGQPQ AGXDD AGYGG AIDQK AIDYY ALVPJ CGR CUY CVF ECM EIF NPM 7TK 7U7 C1K K9. 7X8 |
| ID | FETCH-LOGICAL-i3521-eb2786e2215c4a29da53fb93aaa7f0db35f925bdcf34872b5a0f6c69359b9cb53 |
| IEDL.DBID | DR2 |
| ISSN | 0017-8748 1526-4610 |
| IngestDate | Fri Jul 11 13:35:24 EDT 2025 Fri Jul 11 15:37:44 EDT 2025 Fri Jul 25 19:49:10 EDT 2025 Thu Apr 03 06:52:26 EDT 2025 Wed Aug 20 01:22:12 EDT 2025 Wed Oct 30 09:48:03 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Keywords | migraine progression migraine triptan chronic migraine acute treatment nonsteroidal anti-inflammatory drug |
| Language | English |
| License | 2013 American Headache Society. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-i3521-eb2786e2215c4a29da53fb93aaa7f0db35f925bdcf34872b5a0f6c69359b9cb53 |
| Notes | ark:/67375/WNG-CN7RFZ9H-X McNeil-Janssen Scientific Affairs LLC, Raritan, NJ (MJSA) National Institutes of Health, National Institutes of Neurological Disorders and Stroke - No. K23048288 istex:A3625EC1995A188DA7C8B7A5C6D4ADF3DCBAD1EE GlaxoSmithKline, Research Triangle Park, NC Table S1. Inferential Statistics for Demographic Characteristics in the First Year of a Couplet as a Function of Outcome in the Second Year of the Couplet. Table S2. Full Nonsteroidal Anti-Inflammatory Drug (NSAID) Use by Headache Day/Month Models. Table S3. Full Triptan Use by Headache Day/Month Models. ArticleID:HEAD12201 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 ObjectType-Article-2 ObjectType-Feature-1 |
| PMID | 23992516 |
| PQID | 1530215671 |
| PQPubID | 24968 |
| PageCount | 16 |
| ParticipantIDs | proquest_miscellaneous_1492653627 proquest_miscellaneous_1461882854 proquest_journals_1530215671 pubmed_primary_23992516 wiley_primary_10_1111_head_12201_HEAD12201 istex_primary_ark_67375_WNG_CN7RFZ9H_X |
| PublicationCentury | 2000 |
| PublicationDate | 2013-11 November/December 2013 2013 Nov-Dec 20131101 |
| PublicationDateYYYYMMDD | 2013-11-01 |
| PublicationDate_xml | – month: 11 year: 2013 text: 2013-11 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Mt. Royal |
| PublicationTitle | Headache |
| PublicationTitleAlternate | Headache: The Journal of Head and Face Pain |
| PublicationYear | 2013 |
| Publisher | Blackwell Publishing Ltd Wiley Subscription Services, Inc |
| Publisher_xml | – name: Blackwell Publishing Ltd – name: Wiley Subscription Services, Inc |
| References | Little RJA, Rubin DB. Statistical Analysis with Missing Data, 2nd edn. New York: John Wiley; 2002. Buse DC, Pearlman SH, Reed ML, Serrano D, Ng-Mak DS, Lipton RB. Opioid use and dependence among persons with migraine: Results of the AMPP study. Headache. 2012;52:18-36. Scher AI, Stewart WF, Ricci JA, et al. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain. 2003;106:81-89. Ashina S, Lyngberg A, Jensen R. Headache characteristics and chronification of migraine and tension-type headache: A population-based study. Cephalalgia. 2010;30:943-952. Serrano D, Manack AB, Reed ML, et al. Cost and predictors of lost productive time in chronic migraine and episodic migraine: Results from the American Migraine Prevalence and Prevention (AMPP) study. Value Health. 2013;16:31-38. International Headache Society. The international classification of headache disorders, 2nd edition. Cephalalgia. 2004;24(Suppl. 1):9-160. Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: A race against the development of central sensitization. Ann Neurol. 2004;55:27-36. Lipton RB, Stewart WF, Sawyer J, Edmeads JG. Clinical utility of an instrument assessing migraine disability: The Migraine Disability Assessment (MIDAS) questionnaire. Headache. 2001;41:854-861. Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology. 2008;71:1821-1828. Couch JR, Lipton RB, Stewart WF, et al. Head or neck injury increases the risk of chronic daily headache: A population-based study. Neurology. 2007;69:1169-1177. Lipton RB, Bigal ME, Ashina S, et al. Cutaneous allodynia in the migraine population. Ann Neurol. 2008;63:148-158. Smith TR, Sunshine A, Stark SR, et al. Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache. 2005;45:983-991. Bigal ME, Rapoport AM, Sheftell FD, et al. Transformed migraine and medication overuse in a tertiary headache centre: Clinical characteristics and treatment outcomes. Cephalalgia. 2004;24:483-490. Cleves C, Tepper SJ. Sumatriptan/naproxen sodium combination for the treatment of migraine. Expert Rev Neurother. 2008;8:1289-1297. Buse DC, Manack AN, Fanning K, et al. Chronic migraine prevalence, disability, and sociodemographic factors: Results from the American Migraine Prevalence and Prevention study. Headache. 2012;52:1456-1470. Bigal ME, Rapaport AM, Lipton RB, et al. Assessment of migraine disability using the Migraine Disability Assessment (MIDAS) questionnaire: A comparison of chronic migraine with episodic migraine. Headache. 2008;43:336-342. Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: Burden, diagnosis and satisfaction with treatment. Neurology. 2008;71:559-566. Rapoport A, Stang P, Gutterman DL. Analgesic rebound headache in clinical practice: Data from a physician survey. Headache. 1996;36:14-19. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: A race against the development of cutaneous allodynia. Ann Neurol. 2004;55:19-26. Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006;26:742-746. Silberstein S, Diener HD, Lipton RB, et al. Epidemiology, risk factors, and treatment of chronic migraine: A focus on topiramate. Headache. 2008;48:1087-1095. Lipton RB, Stewart WF, Simon D. Medical consultation for migraine: Results from the American Migraine Study. Headache. 1998;38:87-96. Manack AB, Buse DC, Serrano D, et al. Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. Neurology. 2011;76:711-718. Brandes JL, Kudrow D, Stark SR, et al. Sumatriptan-naproxen for acute treatment of migraine: A randomized trial. JAMA. 2007;297:1443-1454. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: Results from the American Migraine Study II. Headache. 2001;41:638-645. Bussone G, Usai S, Grazzi L, et al. Disability and quality of life in different primary headaches: Results from Italian studies. Neurol Sci. 2004;25:S105-S107. Ashina S, Serrano D, Lipton RB, et al. Depression and risk of transformation of episodic to chronic migraine. J Headache Pain. 2012;13:615-624. Schafer JL. Analysis of Incomplete Multivariate Data. London: Chapman & Hall; 1997. Lipton RB. Tracing transformation: Chronic migraine classification, progression, and epidemiology. Neurology. 2009;72(5 Suppl.):S3-S7. Bigal ME, Serrano D, Buse D, Scher AI, Stewart WF, Lipton RB. 2008 Wolff Award of the American Headache Society. Migraine medications and evolution from episodic to chronic migraine: A longitudinal population-based study. Headache. 2008;48:1157-1168. Buse DC, Manack A, Serrano D, et al. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry. 2010;81:428-432. Zwart JA, Dyb G, Hagen K, et al. Analgesic overuse among subjects with headache, neck, and low-back pain. Neurology. 2004;62:1540-1544. Meletiche DM, Lofland JH, Young WB. Quality-of-life differences between patients with episodic and transformed migraine. Headache. 2001;41:573-578. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343-349. Liebenstein M, Bigal M, Sheftell F, Tepper S, Rapoport A, Lipton R. Validation of the chronic daily headache questionnaire (CDH-Q). Headache. 2007;47:760-761. Natoli JL, Manack A, Lipton RB, et al. Global prevalence of chronic migraine: A systematic review. Cephalalgia. 2010;30:599-609. Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near-daily headaches: Field trial of revised IHS criteria. Neurology. 1996;47:871-875. Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011;31:301-315. Waeber C, Moskowitz MA. Migraine as an inflammatory disorder. Neurology. 2005;(Suppl. 2)64:S9-S15. Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001;56(6 Suppl. 1):S20-S28. 2004; 62 2010 2004; 25 2004; 24 2011; 31 1997 2005; 64 2008; 8 2011; 76 2002 2010; 81 1996; 36 2012; 13 2008; 71 2001; 41 2005; 45 2012; 52 1998; 38 2004; 55 2003; 106 2013; 16 2009; 72 2007; 297 2006; 26 2008; 48 2008; 43 2008; 63 1996; 47 2001; 56 2007; 68 2010; 30 2007; 69 2007; 47 |
| References_xml | – reference: Buse DC, Manack A, Serrano D, et al. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry. 2010;81:428-432. – reference: Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: A race against the development of cutaneous allodynia. Ann Neurol. 2004;55:19-26. – reference: Bigal ME, Rapoport AM, Sheftell FD, et al. Transformed migraine and medication overuse in a tertiary headache centre: Clinical characteristics and treatment outcomes. Cephalalgia. 2004;24:483-490. – reference: Smith TR, Sunshine A, Stark SR, et al. Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache. 2005;45:983-991. – reference: Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001;56(6 Suppl. 1):S20-S28. – reference: Little RJA, Rubin DB. Statistical Analysis with Missing Data, 2nd edn. New York: John Wiley; 2002. – reference: Manack AB, Buse DC, Serrano D, et al. Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. Neurology. 2011;76:711-718. – reference: Ashina S, Lyngberg A, Jensen R. Headache characteristics and chronification of migraine and tension-type headache: A population-based study. Cephalalgia. 2010;30:943-952. – reference: Couch JR, Lipton RB, Stewart WF, et al. Head or neck injury increases the risk of chronic daily headache: A population-based study. Neurology. 2007;69:1169-1177. – reference: International Headache Society. The international classification of headache disorders, 2nd edition. Cephalalgia. 2004;24(Suppl. 1):9-160. – reference: Bigal ME, Serrano D, Buse D, Scher AI, Stewart WF, Lipton RB. 2008 Wolff Award of the American Headache Society. Migraine medications and evolution from episodic to chronic migraine: A longitudinal population-based study. Headache. 2008;48:1157-1168. – reference: Liebenstein M, Bigal M, Sheftell F, Tepper S, Rapoport A, Lipton R. Validation of the chronic daily headache questionnaire (CDH-Q). Headache. 2007;47:760-761. – reference: Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: Burden, diagnosis and satisfaction with treatment. Neurology. 2008;71:559-566. – reference: Ashina S, Serrano D, Lipton RB, et al. Depression and risk of transformation of episodic to chronic migraine. J Headache Pain. 2012;13:615-624. – reference: Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: A race against the development of central sensitization. Ann Neurol. 2004;55:27-36. – reference: Lipton RB, Bigal ME, Ashina S, et al. Cutaneous allodynia in the migraine population. Ann Neurol. 2008;63:148-158. – reference: Serrano D, Manack AB, Reed ML, et al. Cost and predictors of lost productive time in chronic migraine and episodic migraine: Results from the American Migraine Prevalence and Prevention (AMPP) study. Value Health. 2013;16:31-38. – reference: Zwart JA, Dyb G, Hagen K, et al. Analgesic overuse among subjects with headache, neck, and low-back pain. Neurology. 2004;62:1540-1544. – reference: Waeber C, Moskowitz MA. Migraine as an inflammatory disorder. Neurology. 2005;(Suppl. 2)64:S9-S15. – reference: Schafer JL. Analysis of Incomplete Multivariate Data. London: Chapman & Hall; 1997. – reference: Meletiche DM, Lofland JH, Young WB. Quality-of-life differences between patients with episodic and transformed migraine. Headache. 2001;41:573-578. – reference: Silberstein S, Diener HD, Lipton RB, et al. Epidemiology, risk factors, and treatment of chronic migraine: A focus on topiramate. Headache. 2008;48:1087-1095. – reference: Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: Results from the American Migraine Study II. Headache. 2001;41:638-645. – reference: Rapoport A, Stang P, Gutterman DL. Analgesic rebound headache in clinical practice: Data from a physician survey. Headache. 1996;36:14-19. – reference: Bigal ME, Rapaport AM, Lipton RB, et al. Assessment of migraine disability using the Migraine Disability Assessment (MIDAS) questionnaire: A comparison of chronic migraine with episodic migraine. Headache. 2008;43:336-342. – reference: Natoli JL, Manack A, Lipton RB, et al. Global prevalence of chronic migraine: A systematic review. Cephalalgia. 2010;30:599-609. – reference: Brandes JL, Kudrow D, Stark SR, et al. Sumatriptan-naproxen for acute treatment of migraine: A randomized trial. JAMA. 2007;297:1443-1454. – reference: Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343-349. – reference: Lipton RB, Stewart WF, Simon D. Medical consultation for migraine: Results from the American Migraine Study. Headache. 1998;38:87-96. – reference: Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006;26:742-746. – reference: Buse DC, Manack AN, Fanning K, et al. Chronic migraine prevalence, disability, and sociodemographic factors: Results from the American Migraine Prevalence and Prevention study. Headache. 2012;52:1456-1470. – reference: Lipton RB, Stewart WF, Sawyer J, Edmeads JG. Clinical utility of an instrument assessing migraine disability: The Migraine Disability Assessment (MIDAS) questionnaire. Headache. 2001;41:854-861. – reference: Scher AI, Stewart WF, Ricci JA, et al. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain. 2003;106:81-89. – reference: Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011;31:301-315. – reference: Lipton RB. Tracing transformation: Chronic migraine classification, progression, and epidemiology. Neurology. 2009;72(5 Suppl.):S3-S7. – reference: Bussone G, Usai S, Grazzi L, et al. Disability and quality of life in different primary headaches: Results from Italian studies. Neurol Sci. 2004;25:S105-S107. – reference: Cleves C, Tepper SJ. Sumatriptan/naproxen sodium combination for the treatment of migraine. Expert Rev Neurother. 2008;8:1289-1297. – reference: Buse DC, Pearlman SH, Reed ML, Serrano D, Ng-Mak DS, Lipton RB. Opioid use and dependence among persons with migraine: Results of the AMPP study. Headache. 2012;52:18-36. – reference: Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology. 2008;71:1821-1828. – reference: Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near-daily headaches: Field trial of revised IHS criteria. Neurology. 1996;47:871-875. – volume: 63 start-page: 148 year: 2008 end-page: 158 article-title: Cutaneous allodynia in the migraine population publication-title: Ann Neurol – volume: 30 start-page: 943 year: 2010 end-page: 952 article-title: Headache characteristics and chronification of migraine and tension‐type headache: A population‐based study publication-title: Cephalalgia – volume: 24 start-page: 9 issue: Suppl. 1 year: 2004 end-page: 160 article-title: The international classification of headache disorders, 2nd edition publication-title: Cephalalgia – volume: 30 start-page: 599 year: 2010 end-page: 609 article-title: Global prevalence of chronic migraine: A systematic review publication-title: Cephalalgia – volume: 69 start-page: 1169 year: 2007 end-page: 1177 article-title: Head or neck injury increases the risk of chronic daily headache: A population‐based study publication-title: Neurology – volume: 48 start-page: 1087 year: 2008 end-page: 1095 article-title: Epidemiology, risk factors, and treatment of chronic migraine: A focus on topiramate publication-title: Headache – volume: 16 start-page: 31 year: 2013 end-page: 38 article-title: Cost and predictors of lost productive time in chronic migraine and episodic migraine: Results from the American Migraine Prevalence and Prevention (AMPP) study publication-title: Value Health – volume: 56 start-page: S20 issue: 6 Suppl. 1 year: 2001 end-page: S28 article-title: Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache‐related disability publication-title: Neurology – volume: 52 start-page: 18 year: 2012 end-page: 36 article-title: Opioid use and dependence among persons with migraine: Results of the AMPP study publication-title: Headache – volume: 41 start-page: 573 year: 2001 end-page: 578 article-title: Quality‐of‐life differences between patients with episodic and transformed migraine publication-title: Headache – volume: 297 start-page: 1443 year: 2007 end-page: 1454 article-title: Sumatriptan‐naproxen for acute treatment of migraine: A randomized trial publication-title: JAMA – volume: 55 start-page: 27 year: 2004 end-page: 36 article-title: Analgesic triptan action in an animal model of intracranial pain: A race against the development of central sensitization publication-title: Ann Neurol – volume: 64 start-page: S9 issue: Suppl. 2 year: 2005 end-page: S15 article-title: Migraine as an inflammatory disorder publication-title: Neurology – volume: 76 start-page: 711 year: 2011 end-page: 718 article-title: Rates, predictors, and consequences of remission from chronic migraine to episodic migraine publication-title: Neurology – volume: 47 start-page: 871 year: 1996 end-page: 875 article-title: Classification of daily and near‐daily headaches: Field trial of revised IHS criteria publication-title: Neurology – volume: 13 start-page: 615 year: 2012 end-page: 624 article-title: Depression and risk of transformation of episodic to chronic migraine publication-title: J Headache Pain – volume: 36 start-page: 14 year: 1996 end-page: 19 article-title: Analgesic rebound headache in clinical practice: Data from a physician survey publication-title: Headache – volume: 71 start-page: 1821 year: 2008 end-page: 1828 article-title: Excessive acute migraine medication use and migraine progression publication-title: Neurology – volume: 71 start-page: 559 year: 2008 end-page: 566 article-title: Chronic migraine in the population: Burden, diagnosis and satisfaction with treatment publication-title: Neurology – volume: 45 start-page: 983 year: 2005 end-page: 991 article-title: Sumatriptan and naproxen sodium for the acute treatment of migraine publication-title: Headache – volume: 26 start-page: 742 year: 2006 end-page: 746 article-title: New appendix criteria open for a broader concept of chronic migraine publication-title: Cephalalgia – year: 2010 – volume: 62 start-page: 1540 year: 2004 end-page: 1544 article-title: Analgesic overuse among subjects with headache, neck, and low‐back pain publication-title: Neurology – volume: 81 start-page: 428 year: 2010 end-page: 432 article-title: Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers publication-title: J Neurol Neurosurg Psychiatry – volume: 8 start-page: 1289 year: 2008 end-page: 1297 article-title: Sumatriptan/naproxen sodium combination for the treatment of migraine publication-title: Expert Rev Neurother – volume: 24 start-page: 483 year: 2004 end-page: 490 article-title: Transformed migraine and medication overuse in a tertiary headache centre: Clinical characteristics and treatment outcomes publication-title: Cephalalgia – volume: 41 start-page: 638 year: 2001 end-page: 645 article-title: Migraine diagnosis and treatment: Results from the American Migraine Study II publication-title: Headache – volume: 25 start-page: S105 year: 2004 end-page: S107 article-title: Disability and quality of life in different primary headaches: Results from Italian studies publication-title: Neurol Sci – year: 2002 – volume: 31 start-page: 301 year: 2011 end-page: 315 article-title: Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS) publication-title: Cephalalgia – year: 1997 – volume: 55 start-page: 19 year: 2004 end-page: 26 article-title: Defeating migraine pain with triptans: A race against the development of cutaneous allodynia publication-title: Ann Neurol – volume: 43 start-page: 336 year: 2008 end-page: 342 article-title: Assessment of migraine disability using the Migraine Disability Assessment (MIDAS) questionnaire: A comparison of chronic migraine with episodic migraine publication-title: Headache – volume: 68 start-page: 343 year: 2007 end-page: 349 article-title: Migraine prevalence, disease burden, and the need for preventive therapy publication-title: Neurology – volume: 38 start-page: 87 year: 1998 end-page: 96 article-title: Medical consultation for migraine: Results from the American Migraine Study publication-title: Headache – volume: 52 start-page: 1456 year: 2012 end-page: 1470 article-title: Chronic migraine prevalence, disability, and sociodemographic factors: Results from the American Migraine Prevalence and Prevention study publication-title: Headache – volume: 41 start-page: 854 year: 2001 end-page: 861 article-title: Clinical utility of an instrument assessing migraine disability: The Migraine Disability Assessment (MIDAS) questionnaire publication-title: Headache – volume: 72 start-page: S3 issue: 5 Suppl. year: 2009 end-page: S7 article-title: Tracing transformation: Chronic migraine classification, progression, and epidemiology publication-title: Neurology – volume: 106 start-page: 81 year: 2003 end-page: 89 article-title: Factors associated with the onset and remission of chronic daily headache in a population‐based study publication-title: Pain – volume: 48 start-page: 1157 year: 2008 end-page: 1168 article-title: Migraine medications and evolution from episodic to chronic migraine: A longitudinal population‐based study publication-title: Headache – volume: 47 start-page: 760 year: 2007 end-page: 761 article-title: Validation of the chronic daily headache questionnaire (CDH‐Q) publication-title: Headache |
| SSID | ssj0004696 |
| Score | 2.3151457 |
| Snippet | Objectives
To assess the influence of triptan or nonsteroidal anti‐inflammatory drug (NSAID) use on the likelihood of developing chronic migraine (CM) among... To assess the influence of triptan or nonsteroidal anti-inflammatory drug (NSAID) use on the likelihood of developing chronic migraine (CM) among persons with... Objectives To assess the influence of triptan or nonsteroidal anti-inflammatory drug (NSAID) use on the likelihood of developing chronic migraine (CM) among... |
| SourceID | proquest pubmed wiley istex |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 1548 |
| SubjectTerms | acute treatment Adult Anti-Inflammatory Agents, Non-Steroidal - adverse effects Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Chronic Disease chronic migraine Data processing Dose-Response Relationship, Drug Female Follow-Up Studies Headaches Humans Longitudinal Studies Male Middle Aged migraine Migraine Disorders - chemically induced Migraine Disorders - drug therapy Migraine Disorders - epidemiology migraine progression nonsteroidal anti-inflammatory drug Nonsteroidal anti-inflammatory drugs Piperidines - adverse effects Piperidines - therapeutic use Population Surveillance - methods Prevalence Quality of life Serotonin 5-HT1 Receptor Agonists - adverse effects Serotonin 5-HT1 Receptor Agonists - therapeutic use Sumatriptan - adverse effects Sumatriptan - therapeutic use triptan Tryptamines - adverse effects Tryptamines - therapeutic use United States - epidemiology |
| Title | Impact of NSAID and Triptan Use on Developing Chronic Migraine: Results From the American Migraine Prevalence and Prevention (AMPP) Study |
| URI | https://api.istex.fr/ark:/67375/WNG-CN7RFZ9H-X/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fhead.12201 https://www.ncbi.nlm.nih.gov/pubmed/23992516 https://www.proquest.com/docview/1530215671 https://www.proquest.com/docview/1461882854 https://www.proquest.com/docview/1492653627 |
| Volume | 53 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bi9QwFA7LPogv3i_VVSKIqNChSZOmEV-GnR1nhRmWcQcHQULSpLKstjKdAfUf-K_NSS-uIoK-FXIhbXLS7yTn-w5Cj8uSJjYxMjaO5zHLchLnVOvYEpHmiSN5aeC8Y77IZiv2es3Xe-hlz4Vp9SGGAzewjLBfg4Fr01wwcshhPyKUBvIWBGsBIlrSC6TIkJyr3YYFyzttUgjj-dnUQ1L4ml_-hC9_havhfzO9it73I23DTM5Hu60ZFd9-E3H831e5hq50QBSP25VzHe256ga6NO-u2m-i78eBP4nrEi_ejI8nWFcWn8IWoyu8ahyuKzwZGFe4E9nF87MPkHTCvcBL1-w-bhs83dSfsIeZuL8cGupg0I_SgfUUeu_lpHzPT8fzk5NnGKIcv95Cq-nR6eEs7vI2xGcezpHYO-sizxz1aKJgmkqreVoamWqtRZlYk_JSUm5sUabeXaKG66TMigw4wkYWhqe30X5VV-4uwlwzSaT1PmqqGdOFZNSJxDe0wnqoZSP0JMyf-txqcyi9OYdQNcHV28UrdbgQy-k7OVPrCB30E6w6K20UgZRJ3oEVJEKPhmJvX3BpoitX7xpwjUgOMn_sb3UkzbiHAiJCd9rFMwwIuMMeQ2YReh6WwFDQe18w-SpMvpodjSfh6d6_VL6PLlPI0REIkgdof7vZuQceKW3Nw2ARPwBtigyw |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3NbtQwELaqIgGX8g-BAkYCBEhZJc6vkTismi5Z2kTVsitWXIwdO1VVyKLNrqC8AQ_Dq_BMeJwfCkJIHHrgFsmOZdkz42_smW8QeliWxJGOoLZQQWz7YezaMeHclm7kxY5y41LAfUeWh-nMfzUP5hvoW5cL0_BD9BduoBnGXoOCw4X0KS2HIvYDl-gTrI2p3FMnn7THVr8YJ3p7HxEy2p3upHZbVMA-0ljDtbUnGcWhIvqoK3xOqOSBVwrqcc6j0pHCC0pKAiGL0tNYnoiAO2VYhJDAKmghoEiEtvjnoIQ4UPUnE3IqDdOUA2sMf-THLRsqBA79nKsGwbB_n_-EaH8FyOaEG11C37u1aQJbjgfrlRgUX36jjfxvFu8y2mqxNh42ynEFbajqKjqftdEE19DXsUkRxYsS56-H4wTzSuIpWFFe4Vmt8KLCSZ9UhlseYZwdHUJdDfUcT1S9fr-q8Wi5-IA1ksbd-1ffBwNFFjeJXWb0jjFLj_xkmB0cPMUQyHlyHc3OZCFuoM1qUalbCAfcpy6V2g33uO_zgvpERY7-UUZSo0lpocdGYNjHhn6E8eUxRONFAXuTv2Q7eTQZvaUpm1tou5Mo1hqimrlQFUr76JFroQd9szYh8C7EK7VY1-D9uTEwGfp_60NJGGi0E1noZiOt_YQgPVrD5NBCz4zM9Q2dgwnCxoywsXR3mJiv2__S-T66kE6zfbY_zvfuoIsESpKYfNBttLlartVdDQxX4p5RR4zenbUI_wDMAGup |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3bbtQwELWqIlW8cL-kFDASIEDKKnGuRuJh1TTsUjZaLV2x4sXYsYOqlqTa7ArKH_Av_Ar_hMe5UBBC4qEPvEWyY1n2zPiMPWcGoYdFQRzpCGoLFcS2H8auHRPObelGXuwoNy4E3HdMsnA0918tgsUG-tZxYZr8EP2FG2iGsdeg4CeyOKPkUMN-4BJ9gLUhlfvq9JN22OoX40Tv7iNC0r2D3ZHd1hSwDzXUcG3tSEZxqIg-6XKfEyp54BWCepzzqHCk8IKCkkDIvPA0lCci4E4R5iHwVwXNBdSI0Ab_gh86FApFJDNyhoVpqoE1dj_y4zYZKsQN_ZyrxsCwfZ__BGh_xcfmgEsvo-_d0jRxLUeD9UoM8i-_ZY38X9buCrrUIm08bFTjKtpQ5TW0NWljCa6jr2NDEMVVgbM3w3GCeSnxAdhQXuJ5rXBV4qSnlOE2izCeHH6AqhrqOZ6pen28qnG6rD5ijaNx9_rV98GQIIsbWpcZvcuXpUd-MpxMp08xhHGe3kDzc1mIm2izrEp1G-GA-9SlUjvhHvd9nlOfqMjRP8pIaiwpLfTYyAs7aZKPML48gli8KGBvs5dsN4tm6Ts6YgsL7XQCxVozVDMXakJpDz1yLfSgb9YGBF6FeKmqdQ2-nxtDHkP_b30oCQONdSIL3WqEtZ8QkKM1SA4t9MyIXN_QuZcgbMwIGxvtDRPztf0vne-jrWmSstfjbP8OukigHokhg-6gzdVyre5qVLgS94wyYvT-vCX4BwXaalg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impact+of+NSAID+and+Triptan+use+on+developing+chronic+migraine%3A+results+from+the+American+Migraine+Prevalence+and+Prevention+%28AMPP%29+study&rft.jtitle=Headache&rft.au=Lipton%2C+Richard+B&rft.au=Serrano%2C+Daniel&rft.au=Nicholson%2C+Robert+A&rft.au=Buse%2C+Dawn+C&rft.date=2013-11-01&rft.eissn=1526-4610&rft.volume=53&rft.issue=10&rft.spage=1548&rft_id=info:doi/10.1111%2Fhead.12201&rft_id=info%3Apmid%2F23992516&rft.externalDocID=23992516 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0017-8748&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0017-8748&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0017-8748&client=summon |